title: Economic evaluation of dabigatran etexilate in the management of atrial fibrillation in Greece.
abstract: BACKGROUND
  The objective of the present study was to evaluate, from an economic perspective, dabigatran etexilate in comparison to existing pharmaceutical therapeutic options available for the protection of moderate-to-high risk patients with non-valvular atrial fibrillation from cardioembolic risk.
  
  
  METHODS
  An existing Markov model was adapted to the Greek setting to reflect the natural course of the disease and the management of patients with different therapies. The model predicts health and economic outcomes and the implications for the social security system during the course of a patient's lifetime. The data for the population of the model were derived from the international literature and local economic databases.
  
  
  RESULTS
  The incremental cost per quality-adjusted life year (QALY) of dabigatran 150 mg twice daily relative to the other therapies varied from €5547 to €11,762 and that of dabigatran 110 mg twice daily from €7398 to €16,437. The incremental cost per QALY of dabigatran 150 mg relative to aspirin, the least costly option, was €11,762 and relative to warfarin and acenocoumarol, the local standards of care, it was €11,400 and €11,224 respectively, well below the local thresholds of acceptance.
  
  
  CONCLUSIONS
  Dabigatran etexilate may represent a cost-effective option for the prevention of thromboembolic events in AF patients at moderate-to-high risk of stroke or systemic embolism.
authors.affiliation: National School of Public Health, Athens, Greece.
authors.forename: George K
authors.initials: GK
authors.lastname: Andrikopoulos
authors.forename: Vasilis
authors.initials: V
authors.lastname: Fragoulakis
authors.forename: Nikos
authors.initials: N
authors.lastname: Maniadakis
mesh_terms: D000328:Adult; D058833:Antithrombin Proteins; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D001562:Benzimidazoles / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D000069604:Dabigatran; D017850:Economics, Pharmaceutical; D006115:Greece; D006801:Humans; D008875:Middle Aged; D011725:Pyridines / Q000191:economics* / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years; D020521:Stroke / Q000191:economics / Q000209:etiology / Q000517:prevention & control*
chemical_list: D058833:Antithrombin Proteins; D001562:Benzimidazoles; D011725:Pyridines; D000069604:Dabigatran